Previous studies of trastuzumab deruxtecan (DS-8201,T-DXd) combined with PD-1 inhibitor in HER2-positive mouse tumor models also found that the anti-tumor effect of this combination therapy mode was better than that of either single drug therapy [22]. The gene discussed is ERBB2; the disease is neoplasm.